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Background:Non-alcoholic fatty liver disease (NAFLD) refers to the accumulation of hepatic steatosis in the absence
of excess alcohol consumption. The pathogenesis of fatty liver disease and steatohepatitis (NASH) is not fully eluci-
dated, but the commonassociationwith visceral obesity, hyperlipidemia, hypertension and type 2 diabetesmellitus
(T2DM) suggests that it is the hepatic manifestation of metabolic syndrome. Peroxisome proliferator-activated re-
ceptor PPARα and PPARγ aremembers of a family of nuclear receptors involved in themetabolismof lipids and car-
bohydrates, adipogenesis and sensitivity to insulin. The objective of this study was to analyze the polymorphisms
Leu162Val of PPARα and Pro12Ala of PPARγ as genetic risk factors for the development and progression of NAFLD.
Methods: One hundred and three NAFLD patients (89 NASH, 14 pure steatosis) and 103 healthy volunteers were
included. Single nucleotide polymorphisms (SNPs) Leu162Val andPro12Alawere analyzedbypolymerase chain re-
action (PCR) and restriction fragment length polymorphism (RFLP).
Results: NASH patients presented higher BMI, AST and prevalence of T2DM than patients with pure steatosis. A
higher prevalence of 12Ala allele was observed in the NASH Subgroup when compared to Control Group. When
we grouped NASH and Steatosis Subgroups (NAFLD), we found lower serum glucose and more advanced ﬁbrosis
in the Leu162Val SNP. On the other hand, there was no statistical difference in clinical, laboratorial and histological
parameters according to the Pro12Ala SNP.
Conclusions:We documented a lower prevalence of 12Ala allele of gene PPARγ in the NASH Subgroup when com-
pared to Control Group. In NAFLD patients, therewere no associations among the occurrence of Pro12Ala SNPwith
clinical, laboratorial and histological parameters. We also documented more advanced ﬁbrosis in the Leu162Val
SNP. The obtained data suggest that Pro12Ala SNPmay result in protection against liver injury and that Leu162Val
SNP may be involved in the progression of NAFLD.© 2013 Elsevier B.V. All rights reserved.1. Introduction
Nonalcoholic fatty liver disease (NAFLD) includes a simple steatosis
(fat accumulation in hepatocytes without concomitant inﬂammation
or ﬁbrosis) and non-alcoholic steatohepatitis (NASH), with a
necroinﬂammatory component (Matteoni et al., 1999). The diagnosis
of NAFLD requires detection of steatosis by liver histology or imagingdisease; NASH, nonalcoholic
eceptor; SNPs, single nucleotide
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ici).
ights reserved.modalities, and the exclusion of other liver diseases, such as alcoholic
liver disease (AFLD) and viral hepatitis (Bedogni et al., 2005). NAFLD
is a condition which cause concern because it may progress to cirrhosis,
liver failure and hepatocellular carcinoma (de Alwis and Day, 2008).
NAFLD occurs worldwide and it is present in various ethnic groups,
making it the a common liver condition (Das et al., 2010; Fan et al.,
2005; Zelber-Sagi et al., 2006). In Brazilian studies, the most common
histological ﬁnding was NASH with ﬁbrosis in asymptomatic males,
and a signiﬁcant number of cases already presented cirrhosis at themo-
ment of diagnosis (Abdelmalek et al., 2001; Cotrim et al., 2011).
Obesity and insulin resistance (IR) are factors related to NAFLD
(Petta et al., 2009; Vuppalanchi and Chalasani, 2009). Others causes in-
clude parenteral nutrition, use of hepatotoxic drugs, gastric bypass sur-
gery and disorders associated with fatty acid metabolism (Brunt, 2009;
Paschos and Paletas, 2009). Currently, the pathogenesis of NAFLD has
been attributed to the “multiparallel hits” hypothesis, which includes
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stress, interaction between adipose tissuewith hepatocytes and genetic
factors (Smith and Adams, 2011).
Various single nucleotide polymorphisms (SNPs) have been impli-
cated in the predisposition to NAFLD or NASH, including genes encoding
adiponutrin/patatin-like phospholipase-3 (PNPLA3), adiponectin, TNFα,
microsomal triglyceride transfer protein and peroxisome proliferator-
activated receptor (PPAR). The PPARα gene is located on chromosome
22q13.3. Some SNPs in this gene were associated with dyslipidemia, IR,
type 2 diabetes mellitus (T2DM) and cardiovascular disease (Yong
et al., 2008).
The Leu162Val PPARα SNP (rs1800206) represents a nitrogen base
substitution from cytosine (C) to guanine (G), leading to a leucine to
valine amino acid exchange in codon 162 (Flavell et al., 2000; Sapone
et al., 2000). For this SNP, Leu162Leu characterizes the wild homozy-
gous genotype. The substitution of a single nitrogen base characterizes
the heterozygous genotype (Leu162Val), and the substitution of two
basis points to the mutated homozygous (Val162Val).
The PPARγ gene is located on chromosome 3p25 and encodes a nu-
clear transcription factor involved in the expression of hundreds of
genes. In the Pro12Ala PPARγ SNP (rs1801282), the substitution of one
nitrogen base alters the coded amino acid (proline to alanine) in codon
12 in exon 2 (Fajas et al., 1997). The association between the 12Ala var-
iant and IR, T2DM, higher BMI, and obesity has been described in several
studies (Altshuler et al., 2000; Mori et al., 2001). The role of this SNP in
the pathogenesis and progression of fatty liver disease is still debated.
The purpose of this study was to analyze the SNPs Leu162Val and
Pro12Ala of PPARα and PPARγ as genetic risk factors for the develop-
ment and progression of the NAFLD.
2. Materials and methods
2.1. Subjects
This study included 103 outpatients with NAFLD, diagnosed
according to the histopathological ﬁndings from the liver biopsy. The
Control Group consisted of 103 healthy subjects without laboratorial
signs of hepatitis or other liver dysfunctions, and presenting normal
liver ultrasound. All volunteers were registered in a Brazilian university
hospital and provided informed consent according to the institutional
research ethics committee (Proc#7697/2007).
2.2. Liver histology
The grading and staging of all liver biopsy specimens were
conducted by one pathologist specialized in hepatology, and followed
Brunt's criteria. Liver samples were prepared with hematoxylin-eosin,
Masson's trichrome and silver reticulin stains. The presence of more
than 5% steatotic hepatocytes in a liver tissue section was accepted as
the minimum criterion for the histological diagnosis of NAFLD (Brunt,
2010; Brunt et al., 2011). Brieﬂy, histological activity was graded based
on steatosis [grade 0 (no steatosis), grade 1 (5-33%), grade 2 (33-60%)
and grade 3 (N60%)]; lobular inﬂammation (0-3); portal chronic inﬂam-
mation (0-2); ballooning (0-2) and ﬁbrosis scores (0-3). The NAFLD ac-
tivity score (NAS) was used to classify NAFLD into Steato7sis (NAS ≤ 4)
and NASH (NAS ≥ 5) Subgroups. For the present study, the grading of
steatosis, lobular inﬂammation, ballooning and ﬁbrosis was used to
rank the histological ﬁndings into moderate (0 ≤ score ≤ 1) or severe
(score ≥ 2).
3. Methods
3.1. Biochemical analyses
Venous blood samples were obtained after a 12-hour overnight fast.
Plasma glucose, serum aspartate aminotransaminase (AST), alanineaminotransaminase (ALT), gamma glutamyl transferase (GGT), alkaline
phosphatase, iron, ferritin, tryglicerides, total andHDL-cholesterol were
measured in a conventional automated analyzer. Low-density lipopro-
tein cholesterol (LDL-c) was calculated according to the equation of
Friedewald et al. (1972). Serum adiponectin, leptin and insulin levels
weremeasured using enzyme linked immunosorbent assays (Millipore,
Missouri, USA).
3.2. Clinical and nutritional assessment
The subjects' weight and height were measured with standard tech-
niques. The bodymass index (BMI) was calculated by the formula: body
weight (kg) / [height (m)]2. A BMI over 27 kg/m2 deﬁned obesity (Bray,
1992). We selected 30 individuals of each group randomly and they an-
swered a semi-quantitative food consumption frequency questionnaire,
which described food consumption within 6 months prior to the study.
Diabetes mellitus was established in patients with a prior diagnosis of
T2DM and those with glucose concentrations above 100 mg/dL
(Deurenberg et al., 1998; Genuth et al., 2003). Dyslipidemiawas deﬁned
when total cholesterol was above 240 mg/dL or triglycerides above or
equal to 150 mg/dL or LDL-c above or equal to 160 mg/dL or HDL-c
below 40 mg/dL for men and below 50 mg/dL for women (JAMA,
2001). IR was calculated according to the homeostasis model assess-
ment of the insulin resistance index (HOMA-IR), computed through
the formula: [fasting serum insulin (μU/mL) × fasting serum glucose
(mg/dL)] / 405 (Matthews et al., 1985). HOMA above 2.5 deﬁned IR
(Guidorizzi de Siqueira et al., 2005).
3.3. Genotyping of Leu162Val of PPAR-α and Pro12Ala of PPARγ
DNA was isolated from peripheral blood leukocytes by the salting-
out method (Miller et al., 1988). The Leu162Val and Pro12ALA SNPs
were detected through polymerase chain reaction-restriction fragment
length polymorphism (PCR-RFLP) following previously described pro-
tocols (Al-Shali et al., 2004; Vohl et al., 2000). PCR products were
digested overnight at 37 °C with 2 U of Hinf I and 1 U of Hae III restric-
tion enzymes to analyze Leu162Val and Pro12ALA SNPs, respectively. In
both cases, the DNA fragments were visualized on 10% polyacrylamide
gels followed by silver staining (Sanguinetti et al., 1994).
3.4. Statistical analysis
Statistical analysis was performed using the software SAS 9.2 (SAS
Institute Inc, Cary, USA). Continuous variables were presented as
means ± standard deviation. Simple comparison of the clinical data be-
tween NAFLD and Control Groups was performed using the Mann-
Whitney U test. The comparison of the clinical data among the different
genotypes was carried out using the analysis of variance test (ANOVA)
after logarithmic transformation. Genotype and allele distributions in
NAFLD andControl Groupswere analyzed by Fisher's exact test. Concor-
dance to the frequency predicted by the Hardy-Weinberg equilibrium
was assessed by the chi-square test. Logistic regression analyses were
used to assess the association between these SNPs with disease using
sex, age and BMI as covariates at the model. Odds ratio (OR) and the
95% conﬁdence interval (CI) were estimated. Moreover, a logistic
regression analysis was included for the evaluation of the association
between genotypes and histological disease severity. To verify the asso-
ciation between SNPs and comorbidities, Fisher's exact test was used
and the variables were expressed as percentages. The level of signiﬁ-
cance was set at p ≤0.05 in all analyses.
4. Results
The energy (1838.8±281.1 vs 2013.3±539.3 kcal/day, p=0.14) and
carbohydrate (261.5±54.8 vs 230.7±1;66.3 g/day, p=0.06) consump-
tion was similar between the volunteers of NAFLD and Control Group,
Table 1
Demographic and clinical features of NAFLD and Control Groups.
NAFLD Group
(n = 103)
Control Group
(n = 103)
p-Values*
Gender (male/female) 47/56 28/75 b0.01
Age (years) 44.5 ± 2.5 31.9 ± 9.6 b0.01
BMI (kg/m2) 31.3 ± 5.2 23.6 ± 3.0 b0.01
Aspartate aminotransferase (U/L) 46.9 ± 36.3 22.1 ± 4.8 b0.01
Alanine aminotransferase (U/L) 67.9 ± 43.6 18.8 ± 7.5 b0.01
Gamma glutamyltransferase (U/L) 95.1 ± 93.5 24.1 ± 7.6 b0.01
Alkaline phosphatase (U/L) 206.1 ± 80.3 170.1 ± 28.6 b0.01
Iron (ug/dL) 90.2 ± 29.1 116.3 ± 34.2 b0.01
Ferritin (ng/mL) 308.4 ± 270.4 101.2 ± 101.1 b0.01
Total cholesterol (mg/dL) 199.2 ± 41.6 183.0 ± 34.2 b0.01
HDL-c (mg/dL) 43.2 ± 10.0 58.3 ± 13.0 b0.01
LDL-c (mg/dL) 123.9 ± 42.1 107.0 ± 28.5 b0.01
Tryglicerides (mg/dL) 180.8 ± 102.9 88.6 ± 38.2 b0.01
Glucose (mg/dL) 111.9 ± 50.8 77.6 ± 7.9 b0.01
Insulin (μU/mL) 22.2 ± 14.7 7.6 ± 3.4 b0.01
HOMA-IR 6.2 ± 5.0 1.4 ± 0.6 b0.01
Leptin (ng/mL) 25.7 ± 18.9 19.9 ± 17.0 b0.01
Adiponectin (μg/mL) 1.8 ± 1.8 10.9 ± 4.9 b0.01
*Mann-Whitney U test.
Table 3
Allelic and genotypic frequencies of Leu162Val (rs1800206) and Pro12Ala (rs1801282)
SNPs in NAFLD and Control Groups.
Allele/genotype NAFLD Group
(n = 103)
Control
Group*
(n = 103)
NASH
Subgroup
(n = 89)
Steatosis
Subgroup
(n = 14)
SNP Leu162Val Leu-carriers 0.94 1.00 0.94
Val-carriers 0.06 0 0.06
Leu162Leu [n, (%)] 79 (89) 14 (100) 92 (89)
Leu162Val [n, (%)] 10 (11) 0 (0) 11 (11)
Val162Val [n, (%)] 0 (0) 0 (0) 0 (0)
SNP Pro12Ala Pro-carriers 0.93 0.93 0.86
Ala-carriers 0.07 0.07 0.14⁎
Pro12Pro [n, (%)] 76 (85) 11 (79) 77 (75)
Pro12Ala [n, (%)] 13 (15) 3 (21) 23 (22)
Ala12Ala [n, (%)] 0 (0) 0 (0) 3 (3)
⁎ Fisher exact test (p = 0.03) for NASH Subgroup vs. Control Group [OR: 0.48
(0.24-0.96)].
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(59.4±17.8 vs 76.9±24.4 g/day, p=0.004) and protein (74.7±
15.8 vs 95.5±34.4 g/day, p=0.006) intake. Demographic and clinical
features of NAFLD and control subjects are available in Table 1. Obesity
was documented in 87 patients (84%), dyslipidemia in 87 (84%), T2DM
in 41 (40%) and IR in 80 (82%) among all individualswithNAFLD. Demo-
graphic and clinical features of NAFLD patients, classiﬁed according to
the histological diagnosis are shown in Table 2.
4.1. Polymorphisms frequency and correlation with biochemical and
histological features of NAFLD
The allelic and genotypic frequencies of the Leu162Val PPARα and
Pro12Ala PPARγ SNPs in patients with NAFLD and controls are shown
in Table 3. Both SNPs were in accordance with the Hardy-Weinberg
equilibrium. There were no statistical differences in the genotypic and
allelic frequencies of Leu162Val PPARα and Pro12Ala PPARγ SNPs be-
tween NAFLD and Control Groups. However, a statistical differenceTable 2
Demographic and clinical features of NAFLD patients, classiﬁed according to the histolog-
ical diagnosis of NASH or steatosis.
NASH
Subgroup
(n = 89)
Steatosis
Subgroup
(n = 14)
p-Values⁎
Gender (male/female) 39/50 8/6 0.93
Age (years) 44.6 ± 12.3 43.7 ± 13.9 0.82
BMI (kg/m2) 31.9 ± 5.3 27.7 ± 2.7 b0.01
Aspartate aminotransferase (U/L) 49.5 ± 37.7 30.9 ± 20.9 0.01
Alanine aminotransferase (U/L) 70.2 ± 43.2 53.6 ± 45.0 0.07
Gamma glutamyl transferase (U/L) 92.8 ± 81.9 108.7 ± 151.0 0.97
Alkaline phosphatase (U/L) 211.6 ± 81.1 172.3 ± 67.8 0.21
Iron (ug/dL) 90.6 ± 29.0 88.2 ± 31.3 0.89
Ferritin (ng/mL) 320.0 ± 282.5 230.0 ± 151.8 0.39
Total Cholesterol (mg/dL) 197.3 ± 42.4 210.9 ± 35.0 0.28
Tryglicerides (mg/dL) 185.5 ± 107.0 151.4 ± 67.5 0.31
HDL-c (mg/dL) 43.0 ± 10.1 44.5 ± 9.4 0.52
LDL-c (mg/dL) 121.8 ± 43.7 138.0 ± 27.1 0.10
Glucose (mg/dL) 115.1 ± 53.3 88.8 ± 8.9 0.08
Insulin (μU/mL) 22.2 ± 14.0 22.1 ± 19.6 0.69
HOMA-IR 6.4 ± 5.1 4.9 ± 4.6 0.17
Leptin (ng/mL) 26.7 ± 19.4 18.7 ± 12.9 0.19
Adiponectin (μg/mL) 1.7 ± 1.8 2.1 ± 1.7 0.18
Obesity [n, (%)] 75 (84) 12 (86) 1.00
T2DM [n, (%)] 40 (45) 1 (7) b0.01
Dyslipidemia [n, (%)] 76 (85) 11 (79) 0.45
IR [n, (%)] 70 (81) 10 (83) 1.00
⁎ Mann-Whitney U test.was observed in the allelic frequency regarding the Pro12Ala SNP,
with the 12Ala allele being more prevalent in the Control Group when
compared to the NASH Group.
In NAFLD subjects, for the Leu162Val SNP we found 93 subjects
grouped with the wild homozygous genotype, from which 50 were
female, 45.2 ± 12.4 years and a BMI of 31.0 ± 4.8 kg/m2. Among
the 10 individuals with heterozygous genotype, 6 were female,
37.7 ± 11.8 years and a BMI of 34.5 ± 7.7 kg/m2. Thewild homozygous
genotype (Pro12Pro) was documented in 87 individuals, fromwhich 46
were female, 44.6 ± 12.6 years and a BMI of 31.3 ± 5.3 kg/m2. Among
the 16 subjects with heterozygous genotype, 10 were female, 44.1 ±
12.3 years and a BMI of 31.9 ± 5.1 kg/m2. We show the laboratory
data (Table 4) and clinical/liver histopathological ﬁndings (Table 5) of
NAFLD patients according to genotype Leu162Val and Pro12Ala.
5. Discussion
This study underlies the existence of several clinical and laboratorial
differences between NAFLD subjects and healthy controls. Moreover, it
evidences similarities between the NASH and the Steatosis Subgroups,
except for higher values of BMI, serum AST and the prevalence of
T2DM in NASH patients. The NASH Subgroup presented a lower preva-
lence of the PPARγ 12Ala allele when compared to controls. When we
analyzed the NAFLD Group according to PPARα SNPs, lower serum glu-
cose levels and a higher percentage of severe ﬁbrosis were documented
in the Leu162Val. On the other hand, there was no statistical difference
in clinical, laboratorial and histologic data according to the PPARγ SNPs.
In this study, the prevalence of 12Ala allele in the PPARγ SNP was
lower in the NASH Subgroup than in controls. Dongiovanni et al.
(2010) showed that the frequency distributions of Leu162Val and
Pro12Ala SNPs were not different between Italian subjects with NAFLD
and controls (Dongiovanni et al., 2010). In several populations from dif-
ferent ethnic origins, the frequency of 12Ala ranged from 8-20% (Radha
et al., 2006; Yen et al., 1997). Among Brazilians of European descent, the
frequency of 12Ala allele was the same as described for European and
European-derived population (Mattevi et al., 2007).
Different from our ﬁndings, studies of PPARγ in different ethnic pop-
ulations suggest a complex interaction among the Pro12Ala SNP, envi-
ronmental factors and SNPs in other genes. The prevalence of the
Pro12Ala genotype was signiﬁcantly higher in the NAFLD patients,
whose body mass index was higher than 25 kg/m2 (Gupta et al.,
2010). The presence of the 12Ala allele may result in higher sensitivity
to insulin than individuals homozygous for Pro12 (Tavares et al.,
2005). Among indigenous from Brazil there was association between
the Pro12Ala variant and features of metabolic syndrome (Vieira-Filho
Table 4
Laboratorial data of NAFLD patients according to genotype of Leu162Val and Pro12Ala SNPs.
SNP Leu162Val
(n = 103)
SNP Pro12Ala
(n = 103)
Homozygote Leu162Leu
(n = 93)
Heterozygote Leu162Val
(n = 10)
p-Values⁎ Homozygote Pro12Pro
(n = 87)
Heterozygote Pro12Ala
(n = 16)
p-Values⁎
Laboratory data
Aspartate aminotransferase(U/L) 44.9 ± 26.5 65.7 ± 85.7 0.72 45.4 ± 27.1 55.3 ± 68.4 0.93
Alanine aminotransferase (U/L) 68.5 ± 42.7 62.3 ± 53.6 0.08 67.6 ± 42.3 69.6 ± 51.9 0.99
Gamma glutamyl transferase (U/L) 96.0 ± 95.9 85.7 ± 70.8 0.58 93.9 ± 93.7 101.0 ± 95.1 0.70
Alkaline phosphatase (U/L) 205.8 ± 79.3 209.2 ± 94.9 0.57 203.2 ± 80.4 223.1 ± 80.0 0.18
Iron (ug/dL) 90.9 ± 28.7 84.3 ± 33.5 0.28 90.0 ± 29.1 91.6 ± 30.2 0.67
Ferritin (ng/mL) 306.9 ± 266.5 322.6 ± 319.9 0.66 287.9 ± 239.9 417.8 ± 387.5 0.17
Total Cholesterol (mg/dL) 199.7 ± 41.2 194.3 ± 47.5 0.92 196.9 ± 40.8 211.7 ± 45.2 0.23
Tryglicerides (mg/dL) 178.1 ± 103.4 205.6 ± 99.7 0.69 181.7 ± 107.3 176.2 ± 77.6 0.96
HDL-cholesterol (mg/dL) 43.1 ± 10.2 43.8 ± 8.1 0.63 42.8 ± 10.2 44.9 ± 9.3 0.50
LDL-cholesterol(mg/dL) 125.6 ± 43.2 109.5 ± 28.4 0.65 146.5 ± 68.9 119.5 ± 33.4 0.05
Glucose (mg/dL) 113.9 ± 52.4 91.8 ± 22.9 0.05 112.6 ± 51.1 108.6 ± 50.4 0.53
Insulin (μU/mL) 22.0 ± 15.1 24.3 ± 10.3 0.74 22.7 ± 15.4 19.1 ± 9.4 0.39
HOMA-IR 6.2 ± 5.1 6.3 ± 3.5 0.76 6.4 ± 5.3 5.1 ± 2.8 0.38
Leptin (ng/mL) 24.8 ± 18.6 34.9 ± 19.8 0.69 24.4 ± 18.9 32.9 ± 17.3 0.14
Adiponectin (μg/mL) 1.8 ± 1.9 1.5 ± 1.0 0.64 1.8 ± 1.9 1.6 ± 0.9 0.68
⁎ Adjusted for age, gender and BMI.
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lipid serum levels were not documented in the Brazilian population
(Chen et al., 2010). However, there was an association between allele
frequencies for 162Val and dyslipidemia, even after adjustment for alco-
hol consumption and waist-to-rip ratio (Mazzotti et al., 2010).
Our results showed lower fasting glucose in carriers of 162Val allele
and therewas no association between thise SNPwith obesity, T2DM, in-
sulin resistance and dyslipidemia. Some authors did not ﬁnd any associ-
ations between genotype Leu162Val SNP and T2DM (Verdi et al., 2005;
Silbernagel et al., 2009). On the other hand, the meta-analysis
conducted by the Human Genome Epidemiology (HuGE) showed asso-
ciation between 12Ala allele and a reduction in the risk of T2DM (odds
ratio = 0.86, 95% CI: 0.81, 0.90) (Gouda et al., 2010), which agrees with
previous studies (Lohmueller et al., 2003; Ludovico et al., 2007; Parikh
and Groop, 2004). There was no documented association between the
Leu162Val SNP and body fat (Verdi et al., 2005; Silbernagel et al.,
2009), steatosis (Silbernagel et al., 2009) and blood lipid proﬁle (Verdi
et al., 2005). The Leu162Val SNP may be associated with some speciﬁc
blood lipid alterations in diabetic patients (Flavell et al., 2000;
Robitaille et al., 2004; Vohl et al., 2000) as well as in healthy subjects
(Jamshidi et al., 2002; Nielsen et al., 2003; Robitaille et al., 2004).Table 5
Clinical and liver histopathologic ﬁndings of NAFLD patients according to genotype of Leu162V
SNP Leu162Val
(n = 103)
Homozygote Leu162Leu
(n = 93)
Heterozygote Leu162V
(n = 10)
Frequency of comorbidities [n, (%)]
Obesity 79 (85) 8 (80)
T2DM 37 (49) 4 (40)
Dyslipidemia 78 (84) 9 (90)
IR 74 (82) 6 (75)
Histologic classiﬁcation [n, (%)]
Moderate steatosis 31 (33) 5 (50)
Severe steatosis 62 (67) 5 (50)
Moderate lobular inﬂammation 32 (34) 2 (20)
Severe lobular inﬂammation 61 (66) 8 (80)
Moderate ballooning 38 (41) 3 (30)
Severe ballooning 55 (59) 7 (70)
Moderate ﬁbrosis 41 (45) 1 (10)
Severe ﬁbrosis 52 (56) 9 (90)In this study,we observed an association between ﬁbrosis stagewith
the presence of Leu162Val, but not of Pro12Ala. Contrary to our ﬁnding,
Dongiovanni et al. (2010) did not establish association between PPARα
162Val allele with severity of steatosis, necroinﬂammation and ﬁbrose
liver damage in NAFLD (Dongiovanni et al., 2010). Regarding the
Pro12Ala SNP, the presence of the 12Ala allele was not associated with
the progression of NAFLD, although increased anti-inﬂammatory activ-
ity was associated with this SNP in AFLD patients (Rey et al., 2010).
One study limitation was the relatively small sample, especially
when compared to population studies on the subject. However, the
number of patients in the present studywas adequate to analyze the in-
ﬂuence of PPARα and PPARγ SNPs on the susceptibility to and progres-
sion of NAFLD. The inclusion of a Control Group in genotyping is one
of the study's strengths, apart from the simultaneous evaluation of sev-
eral laboratorial variables. On the other hand, we can't rule out the pos-
sibility that a higher BMI and older age in NAFLD patients may have
contributed to the development of the disease. Liver biopsy remains
the gold standard for the diagnosis of NAFLD, but its usage is strictly
clinical and depends on patient consent (Brunt et al., 2011; Cheung
and Sanyal, 2009). In this context, a thorough and updated protocol
of liver biopsy histological parameters was used to rank NASH andal and Pro12Ala SNPs.
SNP Pro12Ala
(n = 103)
al p-Values Homozygote Pro12Pro
(n = 87)
Heterozygote Pro12Ala
(n = 16)
p-Values
0.68 74 (85) 13 (81) 0.71
0.99 35 (40) 6 (38) 1.00
0.61 67 (77) 16 (100) 0.07
0.61 67 (77) 12 (75) 1.00
0.31 29 (33) 7 (44) 0.57
58 (67) 9 (56)
0.49 28 (32) 6 (37) 0.77
59 (68) 10 (62)
0.74 34 (39) 7 (44) 0.78
53 (61) 9 (56)
0.04 35 (40) 7 (44) 0.79
52 (60) 9 (56)
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PPARα and PPARγ, apart from other genes, could be involved in the sus-
ceptibility (Chen et al., 2008) and progression (Rotman et al., 2010) of
NAFLD. Gawrieh et al. (2012) did not ﬁnd any individual effects of
Pro12Ala and C1431T SNPs on the risk of developing NAFLD and
NASH, though the simultaneous occurrence of these SNPs raised the
susceptibility to liver disease. In this same study, it was shown that
the GT haplotype, which comprises both minor alleles, was associated
with inﬂammatory and ﬁbrotic alterations, which in turn indicate
more advanced NAFLD (Gawrieh et al., 2012).
In conclusion, we showed that 12Ala allele of PPARγwas less preva-
lent among NASH patients than the Control Group. There were no asso-
ciations among PPARγ SNPs (Pro12Ala) and clinical, laboratorial and
histological parameters in NAFLD patients. However, we documented
more advanced ﬁbrosis in carriers of the Leu162Val PPARα SNP. The
obtained data suggest that the Pro12Ala SNP may result in protection
against liver injury and that the Leu162Val SNP may be involved in
the progression of NAFLD.
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